Kamada Rui, Sakaguchi Shuya, Kanno Madoka, Ozawa Takaaki, Nakagawa Natsumi, Omichinski James G, Sakaguchi Kazuyasu
Laboratory of Biological Chemistry, Department of Chemistry, Faculty of Science, Hokkaido University, Sapporo, 060-0810, Japan.
Département de Biochimie et Médicine Moléculaire, Université de Montréal, C.P. 6128 Succursale Centre-Ville, Montréal, QC H3C 3J7, Canada.
Chembiochem. 2025 Jul 24:e2500330. doi: 10.1002/cbic.202500330.
Li-Fraumeni syndrome (LFS) is an inherited cancer predisposition disorder caused by heterozygous TP53 mutations. Among these, missense mutations at Arg337-such as R337C and R337H-are common in LFS patients. Although many studies have characterized individual p53 variants in LFS, the impact of tetramerization domain (TD) mutations on wild-type (WT) p53 function remains unclear. Herein, a novel FRET-based assay system that enables the simultaneous detection of heterotetramer formation and p53-dependent transcriptional activity in live cells is developed. These results show that the heteromultimerization of the R337C variant with WT p53 is only slightly reduced compared to WT homotetramers, yet its transcriptional activity is diminished by over 50%. In contrast, the R337H variant forms heterotetramers at near-normal levels but exhibits markedly compromised transcriptional activity. These findings reveal a previously unrecognized dominant-negative-like effect, suggesting reduced p53 function is due not only to decreased tetramer formation but also to diminished heterotetramer stability. Moreover, the LFS-associated p53TD variants show a greater loss of activity against the low-affinity, apoptosis-inducing bax response element than against the high-affinity, cell cycle arrest-related CDKN1A response element. Collectively, this study demonstrates that p53TD mutations can exert dominant-negative effects, advancing the understanding of p53 heteromultimer function in LFS pathogenesis. These mechanistic insights into p53 heterotetramer stability may not only inform genetic screening strategies for LFS but also support future therapeutic approaches aimed at restoring p53 function by stabilizing mutant tetramers.
李-弗劳梅尼综合征(LFS)是一种由杂合型TP53突变引起的遗传性癌症易感性疾病。其中,精氨酸337位点的错义突变,如R337C和R337H,在LFS患者中很常见。尽管许多研究已经对LFS中单个p53变体进行了表征,但四聚化结构域(TD)突变对野生型(WT)p53功能的影响仍不清楚。在此,开发了一种基于荧光共振能量转移(FRET)的新型检测系统,该系统能够在活细胞中同时检测异源四聚体的形成和p53依赖性转录活性。这些结果表明,与WT同源四聚体相比,R337C变体与WT p53的异源多聚化仅略有降低,但其转录活性却降低了50%以上。相比之下,R337H变体以接近正常的水平形成异源四聚体,但转录活性明显受损。这些发现揭示了一种以前未被认识的显性负性样效应,表明p53功能降低不仅是由于四聚体形成减少,还由于异源四聚体稳定性降低。此外,与LFS相关的p53TD变体对低亲和力、诱导凋亡的bax反应元件的活性丧失比对高亲和力、细胞周期停滞相关的CDKN1A反应元件的活性丧失更大。总的来说,这项研究表明p53TD突变可发挥显性负性作用,增进了对LFS发病机制中p53异源多聚体功能的理解。这些对p53异源四聚体稳定性的机制性见解不仅可以为LFS的基因筛查策略提供信息,还可以支持未来旨在通过稳定突变四聚体来恢复p53功能的治疗方法。